Tradestie Institutional Equity Comparison Engine

BMRN vs SYRE โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

BMRN Overall Edge

BMRN Captures Institutional Edge (2โ€“2 Pillars ยท 8โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to BioMarin Pharmaceuticals Inc (BMRN) driven by superior Valuation, Growth & Margin while SYRE counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, BMRN trades at 9.1x Forward P/E with 16.3% operating margin (+32.0% YoY revenue) versus SYRE at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, BMRN sits in CONSOLIDATION (17th %ile IV; Dealer Gamma Walls on Pro) against SYRE sits in UNCLASSIFIED (10th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner BMRN
BMRN 9.1x vs SYRE N/M Fwd P/E
Growth & Margin Winner BMRN
Op Margin 16.3% vs 0.0% ยท YoY +32.0% vs +0.0%
Momentum & Technical Winner SYRE
1Y +7.6% vs +341.7% ยท 52W Pos 42% vs 88%
Options & Structure Winner SYRE
CONSOLIDATION (17th %ile IV) vs UNCLASSIFIED (10th %ile IV)
BMRN NASDAQ
BioMarin Pharmaceuticals Inc
Pharmaceutical Preparations
$58.32
+1.9% 1D
Market Cap $11.0B
1M Return +6.66%
1Y Return +7.56%
Forward P/E 9.1x
Unified AI Score
52.6 / 100 HOLD
Tech 57.0 Fund 61.0 Flow 66.0 Mom 60.0
SYRE NASDAQ
Spyre Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$99.97
-3.88% 1D
Market Cap $9.8B
1M Return +25.11%
1Y Return +341.74%
Forward P/E N/M
Unified AI Score
44.4 / 100 HOLD
Tech 31.0 Fund 33.0 Flow 50.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: BMRN +7.56% SYRE +341.74% Spread: +334.18 pp (SYRE Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
BMRN TTM Op. Margin: 16.3% SYRE TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BMRN vs SYRE. Trailing 12-month operating profitability (BMRN 16.3% vs SYRE 0.0%) and valuation multiples (BMRN 9.1x vs SYRE N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: BMRN (8) vs SYRE (2)
Institutional Metric BMRN SYRE Criterion Row Winner
Market Capitalization Scale $11.0B $9.8B Larger Scale BMRN
Trailing P/E Ratio Valuation 8.8x N/M Lower Multiple BMRN
Forward P/E Ratio Valuation 9.1x N/M Lower Multiple BMRN
Revenue Growth (YoY) Growth +32.0% +0.0% Higher Growth BMRN
Operating Margin (TTM) Profitability 16.3% 0.0% Higher Margin BMRN
Net Profit Margin Profitability -0.5% 0.0% Higher Margin SYRE
Return on Equity (ROE) Capital Efficiency -0.3% -35.0% Higher ROE BMRN
52-Week Range Position Momentum 42% ($49โ€“$71) 88% ($22โ€“$111) Stronger Trend SYRE
Beta / 30D Volatility Risk Regime 0.28ฮฒ ยท 31% Vol 1.75ฮฒ ยท 59% Vol Lower Realized Risk BMRN
Unified Institutional Score Composite Signal 52.6 / 100 (HOLD) 44.4 / 100 (HOLD) Higher Composite BMRN

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full BMRN vs SYRE Buy Guide
BMRN CONSOLIDATION
67d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 17th %ile
IV Regime Compressed (<25th %ile)
Live BMRN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
SYRE UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 10th %ile
IV Regime Compressed (<25th %ile)
Live SYRE Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither BMRN nor SYRE registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.